TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10334140

Group type: EXPERIMENTAL
Intervention: Budesonide via MDI alone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Budesonide via Turbohaler
Number of subjects: 16

Group type: COMPARATOR
Intervention: Budesonide via MDI spacer
Number of subjects: 16

Group type: COMPARATOR
Intervention: Budesonide orally
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Budesonide via Nebulizer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluticasone at 4 mg via MDI spacer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluticasone at 2 mg via MDI spacer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Budesonide at 4 mg via MDI spacer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Budesonide at 2 mg via MDI spacer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Beclomethasone at 4 mg via MDI spacer
Number of subjects: 16
Study: 8951269

Group type: EXPERIMENTAL
Intervention: Continuous negative extrathoracic pressure (CNEP, ‐4 to ‐6 cmH2O)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Continuous negative extrathoracic pressure (CNEP)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard neonatal intensive care (Control)
Number of subjects: 244
Study: 2021655

Group type: EXPERIMENTAL
Intervention: N2O
Number of subjects: 184

Group type: COMPARATOR
Intervention: N2O-free
Number of subjects: 184
Study: 31007049

Group type: EXPERIMENTAL
Intervention: Electronic health record-supported recruitment
Number of subjects: 2423

Group type: COMPARATOR
Intervention: Non-electronic health record recruitment
Number of subjects: 2423
Study: 28646169

Group type: EXPERIMENTAL
Intervention: EpxDialysis (digital messaging platform)
Number of subjects: 0
Study: 26083771

Group type: EXPERIMENTAL
Intervention: Creatine loading (20 g·d⁻¹ for 5 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 23768003

Group type: EXPERIMENTAL
Intervention: VIP ON
Number of subjects: 389

Group type: COMPARATOR
Intervention: Standard AV settings
Number of subjects: 389

Group type: COMPARATOR
Intervention: VIP OFF
Number of subjects: 389
Study: 21809733

Group type: EXPERIMENTAL
Intervention: Kangaroo care (KC) and live harp music therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Kangaroo care (KC) alone
Number of subjects: 52
Study: 19242062

Group type: EXPERIMENTAL
Intervention: NPM1 mutation detection in plasma
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Plasma testing for NPM1 mutations
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: NPM1 mutations
Number of subjects: 98
Study: 17284748

Group type: EXPERIMENTAL
Intervention: Synbiotic preparation (SYN1 + Lactobacillus rhamnosus GG + Bifidobacterium lactis Bb12)
Number of subjects: 80
Study: 15462618

Group type: EXPERIMENTAL
Intervention: Confidence-accuracy calibration for absolute face recognition judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence-accuracy calibration for relative face recognition judgments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence-accuracy calibration for simultaneous mini-lineups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Confidence-accuracy calibration for sequential mini-lineups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Effect of difficulty on CA calibration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative (i.e., new) recognition judgments
Number of subjects: 0
Study: 11442858

Group type: EXPERIMENTAL
Intervention: Tracheal tube (TT) insertion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA) insertion
Number of subjects: 38
Study: 9725476

Group type: EXPERIMENTAL
Intervention: Test formulations (two new formulations)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Test capsule
Number of subjects: 24

Group type: COMPARATOR
Intervention: Test tablet
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference capsule
Number of subjects: 24
Study: 7976288

Group type: EXPERIMENTAL
Intervention: Porous‐coated rigid femoral component
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Smooth, isoelastic femoral component
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (non‐operated side)
Number of subjects: 56
Study: 2926213

Group type: EXPERIMENTAL
Intervention: Dynamic splinting technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Static splinting
Number of subjects: 100
Study: 31323779

Group type: EXPERIMENTAL
Intervention: Beetroot juice (6 mmol nitrate)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (6 mmol nitrate)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Water (placebo)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Beetroot juice and Sodium nitrate
Number of subjects: 22
Study: 28747642

Group type: EXPERIMENTAL
Intervention: docetaxel + fulvestrant (TF)
Number of subjects: 22

Group type: COMPARATOR
Intervention: docetaxel (T)
Number of subjects: 22
Study: 25387843

Group type: EXPERIMENTAL
Intervention: Intracameral injection of vancomycin (1 mg/0.1 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intracameral injection of cefuroxime (1 mg/0.1 ml)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Both groups (vancomycin and cefuroxime)
Number of subjects: 60
Study: 23165105

Group type: EXPERIMENTAL
Intervention: Bio‐Oss(®) Collagen (BOC) grafted site
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control site (empty gap)
Number of subjects: 9
Study: 21192751

Group type: EXPERIMENTAL
Intervention: Automated workplace mental health assessment and intervention
Number of subjects: 463

Group type: COMPARATOR
Intervention: Screening only (Control)
Number of subjects: 463
Study: 18642209

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) combined with intravitreal injection of bevacizumab (1.25 mg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Standard photodynamic therapy (PDT)
Number of subjects: 23
Study: 16564940

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 18

Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 18
Study: 12705984

Group type: EXPERIMENTAL
Intervention: 1% lidocaine (n=55)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Saline (n=43)
Number of subjects: 98
Study: 10902503

Group type: EXPERIMENTAL
Intervention: Practice-oriented interdisciplinary teaching in small groups, including imaging methods (computed tomography, endoscopy, and sonography).
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Practice-oriented interdisciplinary teaching in small groups.
Number of subjects: 300
Study: 8669166

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 15 mg/week in association with Ursodeoxycholic acid (UDCA) 500 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 14
Study: 1571500

Group type: EXPERIMENTAL
Intervention: 4-aminosalicylic acid (4-ASA) enemas
Number of subjects: 40

Group type: COMPARATOR
Intervention: prednisolone-21-phosphate enemas
Number of subjects: 40
Study: 3899970

Group type: EXPERIMENTAL
Intervention: Benzydamine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 31550251

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Suicide Prevention therapy
Number of subjects: 19
Study: 28028714

Group type: EXPERIMENTAL
Intervention: Expert group
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Skilled group
Number of subjects: 15

Group type: COMPARATOR
Intervention: Novice group
Number of subjects: 15
Study: 26952224

Group type: EXPERIMENTAL
Intervention: 7.5mg of 0.5% levobupivacaine with 60mg dextrose (Group I)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 7.5mg of 0.5% levobupivacaine with 80mg dextrose (Group II)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 7.5mg of 0.5% levobupivacaine with 100mg dextrose (Group III)
Number of subjects: 75
Study: 24370543

Group type: EXPERIMENTAL
Intervention: Pylorus-resecting pancreaticoduodenectomy (PrPD)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Pylorus-preserving pancreaticoduodenectomy (PpPD)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (DGE) patients
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Non-DGE patients
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: DGE patients
Number of subjects: 130
Study: 23099329

Group type: EXPERIMENTAL
Intervention: NDV-3 (30 μg Als3p)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: NDV-3 (300 μg Als3p)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 20524773

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow (BM) mononuclear cells prepared using a Sepax device
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Automated systems (the Sepax for processing and the Endosafe device for endotoxin testing)
Number of subjects: 60
Study: 17209217

Group type: EXPERIMENTAL
Intervention: Multivitamin supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-carotene
Number of subjects: 0
Study: 15736118

Group type: EXPERIMENTAL
Intervention: acarbose (150 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: voglibose (0.9 mg/d)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: acarbose (50 mg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: voglibose (0.3 mg)
Number of subjects: 21
Study: 9796842

Group type: EXPERIMENTAL
Intervention: Perindopril
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study: 7713815

Group type: EXPERIMENTAL
Intervention: Water immersion (WE)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Air exercise (AE)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Comparison of AE and WE
Number of subjects: 7
Study: 2515527

Group type: EXPERIMENTAL
Intervention: Misoprostol (800 micrograms daily)
Number of subjects: 64

Group type: COMPARATOR
Intervention: De‐Nol (5 ml four times a day diluted with 15 ml of water)
Number of subjects: 64
Study: 352505

Group type: EXPERIMENTAL
Intervention: Adriamycin
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Actinomycin-D
Number of subjects: 66
Study: 31165641

Group type: EXPERIMENTAL
Intervention: Maceration dressing
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 56
Study: 30322272

Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 206
Study: 30595326

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40mg
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Number of subjects: 240
Study: 26334785

Group type: EXPERIMENTAL
Intervention: Conservative oxygenation strategy with target SpO2 of 88‐92% (n=52)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Liberal oxygenation strategy with target SpO2 of ≥ 96% (n=51)
Number of subjects: 103
Study: 23918588

Group type: EXPERIMENTAL
Intervention: Resveratrol (3g daily for 12 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22192511

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg/day
Number of subjects: 5411

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5411
Study: 20210823

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural 'self-help' style workbook
Number of subjects: 19
Study: 18372721

Group type: EXPERIMENTAL
Intervention: HDBR with TBNP of -15 cmH2O
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HDBR with TBPP of +15 cmH2O
Number of subjects: 8

Group type: COMPARATOR
Intervention: HDBR
Number of subjects: 8
Study: 15781363

Group type: EXPERIMENTAL
Intervention: Artelon TMC Spacer
Number of subjects: 15

Group type: COMPARATOR
Intervention: Trapezium resection arthroplasty with APL stabilization
Number of subjects: 15
Study: 11991875

Group type: EXPERIMENTAL
Intervention: Patients with restrictive lung disease
Number of subjects: 10

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 10
Study: 10094168

Group type: EXPERIMENTAL
Intervention: EHRZ (Ethambutol, Isoniazid, Rifampicin, Pyrazinamide)
Number of subjects: 1023

Group type: COMPARATOR
Intervention: SHRZ (Streptomycin, Isoniazid, Rifampicin, Pyrazinamide)
Number of subjects: 1023
Study: 10172365

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 20
Study: 2286438

Group type: EXPERIMENTAL
Intervention: Steam therapy in a cloth tent (Study Group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no steam therapy)
Number of subjects: 36
Study: 7017244

Group type: EXPERIMENTAL
Intervention: Horse antihuman thymocyte globulin (ATG) added to azathioprine and prednisolone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group receiving azathioprine and prednisolone without ATG
Number of subjects: 50
Study: 31254388

Group type: EXPERIMENTAL
Intervention: Screening cohort (biennially from age 50 to 69 years)
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Not screened cohort
Number of subjects: 100000
Study: 30421455

Group type: EXPERIMENTAL
Intervention: SBP <120 mmHg
Number of subjects: 995

Group type: COMPARATOR
Intervention: SBP 120–130 mmHg
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: SBP 130–140 mmHg
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: SBP 140–150 mmHg
Number of subjects: 995

Group type: EXPERIMENTAL
Intervention: SBP ≥150 mmHg
Number of subjects: 995
Study: 26343332

Group type: EXPERIMENTAL
Intervention: RED-D (modified brief Cognitive Behavioral Therapy delivered telephonically by a mental health professional)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: RED plus usual care
Number of subjects: 1200
Study: 25208663

Group type: EXPERIMENTAL
Intervention: 380 g of farmed Atlantic salmon fillets per week for 15 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 60 g of salmon oil per week for 15 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 42
Study: 22294255

Group type: EXPERIMENTAL
Intervention: Capecitabine, oxaliplatin, cetuximab, and bevacizumab (Arm A)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Capecitabine, oxaliplatin, and cetuximab (Arm B)
Number of subjects: 23
Study: 19963031

Group type: EXPERIMENTAL
Intervention: Black tea (9 g daily for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (hot water)
Number of subjects: 0
Study: 17496286

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 552

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Reperfusion therapy
Number of subjects: 552

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: PCI treatment of re-infarction
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Regional differences in treatment
Number of subjects: 552
Study: 15788681

Group type: EXPERIMENTAL
Intervention: 9-cis-retinoic acid (9-cis-RA)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 12004808

Group type: EXPERIMENTAL
Intervention: Combination of morphine (1 mg x m(‐1)) and ketamine (0.75 mg x m(‐1)) via PCAS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Morphine (1 mg x m(‐1)) via PCAS
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of morphine and ketamine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 42
Study: 10465376

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control (non-recipient volunteers)
Number of subjects: 140
Study: 7789048

Group type: EXPERIMENTAL
Intervention: Voluntary control of breathing task using a spirometer
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Manual tracking task using a joystick (control task)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group of healthy subjects
Number of subjects: 8
Study: 2189149

Group type: EXPERIMENTAL
Intervention: High-dose alternate-day prednisolone
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 107
Study: 7322959

Group type: EXPERIMENTAL
Intervention: Indapamide, 2.5 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclopenthiazide, 0.5 mg daily
Number of subjects: 0
Study: 31694568

Group type: EXPERIMENTAL
Intervention: ROTEM®-guided blood-component transfusion protocol
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: ROTEM®-guided treatment in patients with long CPB-times (> 115 min.; n = 55)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (standard coagulation testing algorithm)
Number of subjects: 104
Study: 27428710

Group type: EXPERIMENTAL
Intervention: Rituximab (RTX) treatment
Number of subjects: 144
Study: 26037941

Group type: EXPERIMENTAL
Intervention: Dabrafenib and trametinib
Number of subjects: 423

Group type: COMPARATOR
Intervention: Dabrafenib only
Number of subjects: 423
Study: 24048773

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 600 mg orally twice daily for 3 days
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo orally twice daily for 3 days
Number of subjects: 88
Study: 21861920

Group type: EXPERIMENTAL
Intervention: Exercise and in-home/telephone follow-up intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise only intervention group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In-home/telephone follow-up only intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 0
Study: 19533304

Group type: EXPERIMENTAL
Intervention: Intravenous moderate doses of human recombinant Epo (epoietin-alpha, 100 or 200 IU/kg/die)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 16337715

Group type: EXPERIMENTAL
Intervention: Higher IGF-I levels (measured by molar ratio of IGF-I to IGFBP-3)
Number of subjects: 590
Study: 16506463

Group type: EXPERIMENTAL
Intervention: Bryan Cervical Disc System
Number of subjects: 33

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 33
Study: 12677302

Group type: EXPERIMENTAL
Intervention: [(18)F]FDG PET
Number of subjects: 15

Group type: COMPARATOR
Intervention: MRI
Number of subjects: 15
Study: 10793596

Group type: EXPERIMENTAL
Intervention: Sitting position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 0
Study: 9012323

Group type: EXPERIMENTAL
Intervention: Mancozeb exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 1334283

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 828

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 828
Study: 6696610

Group type: EXPERIMENTAL
Intervention: Classic conditioning method using bell and pad
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Operant conditioning method with unconditioned stimulus delay of 3 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study: 31580316

Group type: EXPERIMENTAL
Intervention: FITÂ® Lady patch (active patch)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patch (control)
Number of subjects: 40
Study: 28987358

Group type: EXPERIMENTAL
Intervention: Fermented plant extract (FPE) 60 mL
Number of subjects: 44
Study: 24443392

Group type: EXPERIMENTAL
Intervention: Low GI diet
Number of subjects: 265

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 265
Study: 23445275

Group type: EXPERIMENTAL
Intervention: Cow's milk protein (CMP) elimination diet (n=14)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Free diet (n=15)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: CMP elimination diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: Free diet
Number of subjects: 29
Study: 21871686

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5mg daily plus metformin
Number of subjects: 570

Group type: COMPARATOR
Intervention: Placebo plus metformin
Number of subjects: 570
Study: 18974285

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg/day and Olmesartan 40 mg/day administered separately for 10 days
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fixed-dose combination of Amlodipine/Olmesartan 10 mg/40 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fixed-dose combination tablet taken 30 minutes after a high-fat breakfast
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 10 mg to 40 mg with Amlodipine 5 mg to 10 mg
Number of subjects: 5
Study: 17102570

Group type: EXPERIMENTAL
Intervention: Colestimide (3 g/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pravastatin (10 mg)
Number of subjects: 0
Study: 14767300

Group type: EXPERIMENTAL
Intervention: 2 mg controlled release melatonin at night
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11567544

Group type: EXPERIMENTAL
Intervention: Surgical procedures (including osteotomies, debridement by arthroscopy and arthotomy, joint replacement)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Debridement by arthroscopy and arthotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Joint replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative treatment (control group)
Number of subjects: 0
Study: 9438709

Group type: EXPERIMENTAL
Intervention: REPRODUCTION
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: TRACKING
Number of subjects: 8
Study: 8123393

Group type: EXPERIMENTAL
Intervention: Video training with closed circuit television (CCTV)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional training
Number of subjects: 20
Study: 2824710

Group type: EXPERIMENTAL
Intervention: Cisplatin/etoposide (PE)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Ifosfamide/etoposide (IE)
Number of subjects: 144
Study: 31923074

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5%) applied at least 10 minutes before biopsy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lidocaine injection (1%) administered at least 1 minute prior to biopsy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Lidocaine-prilocaine cream (5%)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Lidocaine injection (1%)
Number of subjects: 106
Study: 29299888

Group type: EXPERIMENTAL
Intervention: Pudendal nerve block (PDB-Group) with 0.3 ml/kg 0.25% bupivacaine
Number of subjects: 78

Group type: COMPARATOR
Intervention: Penile nerve block (PNB-Group) with 0.3 ml/kg 0.25% bupivacaine
Number of subjects: 78